Literature DB >> 12193510

Retinopathy of prematurity: recent advances in our understanding.

C M Wheatley1, J L Dickinson, D A Mackey, J E Craig, M M Sale.   

Abstract

Retinopathy of prematurity (ROP) has been recognised as an important cause of childhood visual impairment and blindness since the 1940s when improved facilities and treatment increased the survival rate of premature infants. Although its incidence and severity have been decreasing in developed countries over the past two decades, both are increasing in developing nations. ROP is consequently targeted as an important but avoidable disease. This review provides an updated summary and discussion of much of the work that has been produced through population, animal, cell culture, and genetic research. The authors examine the prevalence, risk factors, and possible causes of the disease with a particular focus on genetic studies. They conclude that while significant reductions in the disease have occurred in developed countries, further research is required to fully understand and prevent the disease. In the meantime, development and implementation of appropriate screening and treatment strategies will be critical in reducing blindness in developing countries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193510      PMCID: PMC1721447          DOI: 10.1136/fn.87.2.f78

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  86 in total

1.  X-linked recessive familial exudative vitreoretinopathy.

Authors:  D A Plager; I K Orgel; F D Ellis; M Hartzer; M T Trese; B S Shastry
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

2.  Risk factors associated with retinopathy of prematurity (ROP) in northern Jutland, Denmark 1990-1993.

Authors:  H Nødgaard; H Andreasen; H Hansen; H T Sørensen
Journal:  Acta Ophthalmol Scand       Date:  1996-06

3.  Increased survival of low birth weight infants: impact on the incidence of retinopathy of prematurity.

Authors:  P H Valentine; J C Jackson; R E Kalina; D E Woodrum
Journal:  Pediatrics       Date:  1989-09       Impact factor: 7.124

4.  Norrie disease in a family with a manifesting female carrier.

Authors:  K B Sims; A R Irvine; W V Good
Journal:  Arch Ophthalmol       Date:  1997-04

5.  Does candidemia predict threshold retinopathy of prematurity in extremely low birth weight (</=1000 g) neonates?

Authors:  M G Karlowicz; P J Giannone; J Pestian; A L Morrow; J Shults
Journal:  Pediatrics       Date:  2000-05       Impact factor: 7.124

6.  Childhood blindness.

Authors:  P G Steinkuller; L Du; C Gilbert; A Foster; M L Collins; D K Coats
Journal:  J AAPOS       Date:  1999-02       Impact factor: 1.220

7.  Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity.

Authors:  D K Wallace; J A Kylstra; S J Phillips; J G Hall
Journal:  J AAPOS       Date:  2000-12       Impact factor: 1.220

8.  A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy.

Authors:  Z Y Chen; E M Battinelli; A Fielder; S Bundey; K Sims; X O Breakefield; I W Craig
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

9.  Blindness in infants and young children.

Authors:  E M Hatfield
Journal:  Sight Sav Rev       Date:  1972

10.  Mutations in the Norrie disease gene.

Authors:  D E Schuback; Z Y Chen; I W Craig; X O Breakefield; K B Sims
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

View more
  13 in total

1.  Causes of severe visual impairment and blindness in children in Ethiopia.

Authors:  V Vedantham; P K Ratnagiri
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

Review 2.  Neurodevelopmental outcomes after preterm birth.

Authors:  Michael Colvin; William McGuire; Peter W Fowlie
Journal:  BMJ       Date:  2004-12-11

3.  Placenta microbiology and histology and the risk for severe retinopathy of prematurity.

Authors:  Minghua L Chen; Elizabeth N Allred; Jonathan L Hecht; Andrew Onderdonk; Deborah VanderVeen; David K Wallace; Alan Leviton; Olaf Dammann
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-01       Impact factor: 4.799

4.  Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats.

Authors:  Jyotirmoy Kusari; Edwin Padillo; Sheila X Zhou; Yanyan Bai; Juanjuan Wang; Zhiming Song; Meili Zhu; Yun-Zheng Le; Daniel W Gil
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-20       Impact factor: 4.799

5.  Hypoxia-induced expression of VEGF splice variants and protein in four retinal cell types.

Authors:  William M Watkins; Gary W McCollum; Sara R Savage; Megan E Capozzi; John S Penn; David G Morrison
Journal:  Exp Eye Res       Date:  2013-09-26       Impact factor: 3.467

6.  Sucrose and non-nutritive sucking for the relief of pain in screening for retinopathy of prematurity: a randomised controlled trial.

Authors:  E M Boyle; Y Freer; Z Khan-Orakzai; M Watkinson; E Wright; J R Ainsworth; N McIntosh
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-01-20       Impact factor: 5.747

Review 7.  Perinatal infection, inflammation, and retinopathy of prematurity.

Authors:  Jennifer Lee; Olaf Dammann
Journal:  Semin Fetal Neonatal Med       Date:  2011-09-07       Impact factor: 3.926

8.  Neurovascular coupling and energy metabolism in the developing brain.

Authors:  M Kozberg; E Hillman
Journal:  Prog Brain Res       Date:  2016-03-22       Impact factor: 2.453

9.  The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity.

Authors:  Przemko Kwinta; Mirosław Bik-Multanowski; Zofia Mitkowska; Tomasz Tomasik; Jacek J Pietrzyk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-11       Impact factor: 3.117

10.  Insulin-like growth factor binding protein-3 in preterm infants with retinopathy of prematurity.

Authors:  Manizheh Mostafa Gharehbaghi; Ali Peirovifar; Karim Sadeghi; Haleh Mostafidi
Journal:  Indian J Ophthalmol       Date:  2012 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.